CNIPA.AI

Company patentsInnovative medicines and biopharmaceuticals

COMPANY PATENT INTELLIGENCE

Novartis Patent Portfolio Analysis

Explore medicines, formulations and related technologies through publications attributed to selected Novartis legal entities.

Partial name or date coverage · counts are lower boundsData as of 2026-11-17Data scope
Search jurisdictions
Worldwide
Applicant-name basis
Dataset-harmonized assignees (not verified current owners)
Source search matches
1,371
Published 2025-01-01 — 2025-12-31 · Source Google Patents
Applicant names included in these statistics
NOVARTIS AG
Publication dates collected
Not recorded in this snapshot
Compare with other companies
Collected patent publications

≥1,371docs

114 per month · peak 2025-03 (196)

Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.

01Key figures

Applications
1,312
By application number; publication and grant count once
Invention
644
49% of applications
Utility model
0
0% of applications
Patent families
465
By the source family ID
Green technology
—
The source has no CPC codes
Concentration
1.04HHI
Sum of squared field shares; higher is more concentrated

INSIGHT 01Fact

89%

89% of applications are in Pharmaceuticals

1,147 applications in this field, 1,095 of them in IPC A61K — the main axis of the portfolio.

Method: Field applications ÷ applications with IPC

02Technology landscape

1,286 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.

  • Instruments
  • Chemistry
  • Mechanical engineering
Explore reviewed themes, sample patents and evidence

03Rhythm

Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.

This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.

Cells count publications only within the collected names and dates. Missing periods are not shown; the company portfolio is incomplete.
Technology field25-0125-0225-0325-0425-0525-0625-0725-0825-0925-1025-1125-12
Pharmaceuticals1178717696979587851011076585
Biotechnology523960434233432745302838
Organic fine chemistry452268223036363131422532
Medical technology91071110411811749
Analysis of biological materials3610222234323
Basic materials chemistry101101241100
Chemical engineering201000200100
Measurement010000110101

Filing years of the collected applications

Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.

  • 20051
  • 20088
  • 200918
  • 20101
  • 201113
  • 20122
  • 20139
  • 201432
  • 201549
  • 201660
  • 201780
  • 201877
  • 201985
  • 2020116
  • 202173
  • 202260
  • 2023208
  • 2024247
  • 2025173Publication lag may still apply

Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.

Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.

04Strategy profile

Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.

Concentration

1.04
0.001.43

Position 3 of 26 published companies.

Method: Sum of squared field shares

Utility model share

0%
0%33%

Position 9 of 26 published companies.

Method: Utility model documents ÷ all documents

Green technology share

—

The source has no CPC codes, so this cannot be computed.

Method: Documents with CPC Y02 ÷ documents with CPC

Manufacturing and inspection share

1.2%
0%50%

Position 19 of 26 published companies.

Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications

05Collaboration

Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.

UNIV PENNSYLVANIA53Other co-applicant · relationship unverified
SERVIER LAB34Other co-applicant · relationship unverified
GENENTECH INC24Other co-applicant · relationship unverified
INTELLIA THERAPEUTICS INC20Other co-applicant · relationship unverified
DANA FARBER CANCER INST INC10Other co-applicant · relationship unverified
KOREA RES INST CHEMICAL TECH9Other co-applicant · relationship unverified
HARVARD COLLEGE8Other co-applicant · relationship unverified
UNIV CALIFORNIA7Other co-applicant · relationship unverified
UNIV LEUVEN KATH7Other co-applicant · relationship unverified
BETH ISRAEL DEACONESS MEDICAL CT INC6Other co-applicant · relationship unverified

Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.

Review the entity list

06Entities and scope

Entity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.

Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.

Showing 1 of 1 entities

Novartis AG

Primary entityVerifiedAll configured names covered
Names collected in this snapshot
Novartis AG
Recorded relationship dates
Not recorded — Not recorded

官方年报确认 Novartis AG 为控股法人;仅纳入其来源标准名,不将 Novartis Pharma AG 等独立法人作为别名。

Review evidence

Relationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.

07Observations

Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.

Technology themes and evidence

Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.

Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.

Showing 2 sample patents · 0 linked observations

Reading samples

Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.

US20250000973A1

Methods of making chimeric antigen receptor-expressing cells

The abstract concerns making CAR-expressing immune effector cells. Claim 1 combines treatment with a multispecific molecule having CD3 and costimulatory binding domains plus specified Fc mutations, introduction of CAR-encoding nucleic acid, and cell harvest. It includes alternative timing or limited-expansion conditions. The focus is the constrained manufacturing process, not every CAR-cell product.

Bibliography and claim evidence
Applicants
Novartis Ag
Application date
2022-08-19
Publication date
2025-01-02
English summary of cited claim evidence
US20250000973A1, claim 1 (reading note, not a verbatim quotation)The abstract concerns making CAR-expressing immune effector cells. Claim 1 combines treatment with a multispecific molecule having CD3 and costimulatory binding domains plus specified Fc mutations, introduction of CAR-encoding nucleic acid, and cell harvest. It includes alternative timing or limited-expansion conditions. The focus is the constrained manufacturing process, not every CAR-cell product.
Legal status
Legal status and current ownership are unverified; applicant names retain the original source attribution.

US20250011428A1

Engineered fc variants

The abstract discusses engineered IgG Fc effects on effector function, receptor binding and stability. Claim 1 specifically requires an immunoglobulin or fragment with one or more antigen-binding domains, a cysteine substitution at EU position 235 in the Fc variant, and reduced effector functions relative to wild type. Other abstract properties are not all limitations of this claim.

Bibliography and claim evidence
Applicants
Novartis Ag
Application date
2022-10-27
Publication date
2025-01-09
English summary of cited claim evidence
US20250011428A1, claim 1 (reading note, not a verbatim quotation)The abstract discusses engineered IgG Fc effects on effector function, receptor binding and stability. Claim 1 specifically requires an immunoglobulin or fragment with one or more antigen-binding domains, a cysteine substitution at EU position 235 in the Fc variant, and reduced effector functions relative to wild type. Other abstract properties are not all limitations of this claim.
Legal status
Legal status and current ownership are unverified; applicant names retain the original source attribution.

08Publication jurisdictions

50 publication offices · 1,371 documents

Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.

  1. USUnited States242
  2. EPEuropean Patent Office publication161
  3. MXMexico114
  4. CNChina103
  5. AUAustralia87
  6. ILIsrael85
  7. JPJapan66
  8. TWTaiwan62
Show 42 more jurisdictions
  1. KRSouth Korea59
  2. WOPCT international publication45
  3. ESSpain42
  4. DKDenmark23
  5. FIFinland20
  6. PLPoland19
  7. PTPortugal19
  8. HRCroatia18
  9. NZNew Zealand18
  10. SISlovenia18
  11. RSSerbia16
  12. LTLithuania15
  13. HUHungary14
  14. ARArgentina13
  15. CLChile11
  16. MYMalaysia10
  17. JOJordan8
  18. PEPeru8
  19. UYUruguay8
  20. CACanada6
  21. COColombia6
  22. MAMorocco6
  23. ZASouth Africa6
  24. DODominican Republic5
  25. FRFrance5
  26. NLNetherlands4
  27. SESweden4
  28. CRCosta Rica3
  29. CYCyprus3
  30. DEGermany3
  31. BEBelgium2
  32. PYParaguay2
  33. SASaudi Arabia2
  34. SMSan Marino2
  35. CHSwitzerland1
  36. CUCuba1
  37. GBUnited Kingdom1
  38. IEIreland1
  39. LULuxembourg1
  40. MDMoldova1
  41. NONorway1
  42. TRTürkiye1

09Documents

1,371 published documentsNewest first
  1. US2025179156A1

    Invention publication

    Angiopoietin-like 4 antibodies and methods of use

    NOVARTIS AG

    BiotechnologyPharmaceuticals

    2025-06-05
  2. US2025179216A1

    Invention publication

    ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES

    GENENTECH INC / NOVARTIS AG

    BiotechnologyPharmaceuticals

    2025-06-05
  3. US2025179447A1

    Invention publication

    Solubilized apyrases, methods and use

    NOVARTIS AG

    BiotechnologyPharmaceuticals

    2025-06-05
  4. US2025179584A1

    Invention publication

    Precision therapy for the treatment of cancer

    NOVARTIS AG

    BiotechnologyPharmaceuticals

    2025-06-05
  5. Compuestos tricíclicos y sus usos

    NOVARTIS AG

    Organic fine chemistryPharmaceuticals

    2025-06-04
  6. EP3972604B1

    Invention grant

    A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria

    NOVARTIS AG

    Pharmaceuticals

    2025-06-04
  7. EP4223760B1

    Invention grant

    Heteroaromatic nmda receptor modulator and uses thereof

    NOVARTIS AG

    Organic fine chemistryPharmaceuticals

    2025-06-04
  8. EP4561538A1

    Invention publication

    Pharmaceutical compositions of tricyclic akr1c3 dependent kars inhibitor and methods for making same

    NOVARTIS AG

    Pharmaceuticals

    2025-06-04
  9. EP4561574A1

    Invention publication

    Dosing regimen for a nlrp3 inhibitor

    NOVARTIS AG

    Pharmaceuticals

    2025-06-04
  10. EP4561608A1

    Invention publication

    Treatment for acute organ injury using cd39, recombinant cd39

    NOVARTIS AG

    BiotechnologyPharmaceuticals

    2025-06-04
  11. EP4561702A1

    Invention publication

    Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention

    NOVARTIS AG

    Analysis of biological materialsPharmaceuticals

    2025-06-04
  12. EP4562010A1

    Invention publication

    Crystalline forms of an akr1c3 dependent kars inhibitor

    NOVARTIS AG

    Organic fine chemistryPharmaceuticals

    2025-06-04
  13. EP4562151A1

    Invention publication

    Improved production of cd39 variants

    NOVARTIS AG

    Biotechnology

    2025-06-04
  14. EP4563150A2

    Invention publication

    New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer

    NOVARTIS AG

    Pharmaceuticals

    2025-06-04
  15. Parenteral formulation comprising siponimod

    NOVARTIS AG

    Pharmaceuticals

    2025-06-04
  16. KR20250079023A

    Invention publication

    삼환식 화합물 및 이의 용도

    NOVARTIS AG

    Organic fine chemistryPharmaceuticals

    2025-06-04
  17. KR20250079180A

    Invention publication

    레미브루티닙의 제조를 위한 합성 방법 및 중간체

    NOVARTIS AG

    Organic fine chemistryPharmaceuticals

    2025-06-04
  18. CN120081946A

    Invention publication

    Method for producing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies

    NOVARTIS AG

    BiotechnologyPharmaceuticals

    2025-06-03
  19. Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents

    NOVARTIS AG

    Organic fine chemistryPharmaceuticals

    2025-06-02
  20. Pharmaceutical combinations and uses thereof

    NOVARTIS AG

    Pharmaceuticals

    2025-06-02

Titles come from the source bibliography. Select a number to read the full document on this site.

Drafting a patent in this field?

Upload your invention disclosure and get an editable draft that follows CNIPA practice.

Start drafting

10Method and sources

Counting units

Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.

Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.

Entity scope

These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.

Search jurisdictions
Worldwide
Applicant-name basis
Dataset-harmonized assignees (not verified current owners)
Applicant names included in these statistics
NOVARTIS AG
Reviewed names not covered
None
Current entity configuration and review evidence

The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.

Novartis AG

Configured aliases: NOVARTIS AG

Original review note: 官方年报确认 Novartis AG 为控股法人;仅纳入其来源标准名,不将 Novartis Pharma AG 等独立法人作为别名。

Review evidence

Data sources

  • Google Patents · PartialPublished 2025-01-01 to 2025-12-31 · retrieved 2026-11-17 · 1,371 included · 0 out of scopeSource and terms

Found a wrong attribution or number? Tell us